Leishmaniasis in HIV infection.
Herein we review the particular aspects of leishmaniasis associated with HIV infection. The data in this review are mainly from papers identified from PubMed searches and from papers in reference lists of reviewed articles and from the authors' personal archives. Epidemiological data of HIV/Leishmania co-infection is discussed, with special focus on the influence of Highly Active Antiretroviral Therapy (HAART) on incidence of leishmaniasis and transmission modalities. Microbiological characteristics, pathogenesis, clinical presentation and specific treatment of the co-infection are also presented.
Paredes
R
R
Internal Medicine Department, Hospital de la Santa Creu i Sant Pau. Av. Sant Antoni Maria Claret 167, 08025 Barcelona. Catalonia. Spain. 34120rpd@comb.es
Munoz
J
J
Diaz
I
I
Domingo
P
P
Gurgui
M
M
Clotet
B
B
D017088:AIDS-Related Opportunistic Infections / Q000175:diagnosis* / Q000188:drug therapy / Q000453:epidemiology / Q000469:parasitology*; D000818:Animals; D000965:Antimony / Q000627:therapeutic use; D000981:Antiprotozoal Agents / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D006678:HIV / Q000472:pathogenicity; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D007891:Leishmania / Q000472:pathogenicity; D007896:Leishmaniasis / Q000150:complications* / Q000175:diagnosis* / Q000188:drug therapy / Q000453:epidemiology; D012307:Risk Factors
D000981:Antiprotozoal Agents; D000965:Antimony